首页> 外文期刊>European archives of oto-rhino-laryngology: Official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) >Perioperative complications and safety of type II thyroplasty (TPII) for adductor spasmodic dysphonia
【24h】

Perioperative complications and safety of type II thyroplasty (TPII) for adductor spasmodic dysphonia

机译:围手术期并发症和II型雌晶型(TPII)的安全性痉挛性痉挛性障碍症

获取原文
获取原文并翻译 | 示例
           

摘要

Type II thyroplasty (TPII) is one of the surgical options offered in the management of adductor spasmodic dysphonia (AdSD); however, there have been no detailed reports of its safety and associated complications during the perioperative period. Our aim was to assess the complications and safety of TPII. TPII was performed for consecutive 15 patients with AdSD from April 2012 through May 2014. We examined retrospectively the perioperative complications, the degree of surgical invasion, and recovery process from surgery. All patients underwent successful surgery under only local anesthesia. Vocal fold erythema was observed in 14 patients and vocal fold edema in 10 patients; however, all of them showed complete resolution within 1 month. No patient experienced severe complications such as acute airway distress or hemorrhage. Fourteen patients were able to have oral from the 1st postoperative morning, with the remaining patient able to have oral intake from the 2nd postoperative day. In addition, no patient experienced aspiration postoperatively. In conclusion, only minor complications were observed in association with TPII in this study. No dysphagia was observed postoperatively, which is an advantage over other treatments. The results of our study suggest that TPII is a safe surgical treatment for AdSD.
机译:II型reyOPrasty(TPII)是在痉挛性痉挛性障碍(ADSD)的管理中提供的外科选择之一;但是,在围手术期期间没有详细报告其安全性和相关的并发症。我们的目标是评估TPII的并发症和安全性。从2012年4月至2014年5月,我们在2012年4月的连续15例ADSD进行了TPII。我们回顾性地研究了围手术期并发症,手术入侵和来自手术的恢复过程。所有患者在仅在局部麻醉下都会发生成功的手术。在10名患者14名患者和声带水肿中观察到声带红斑;但是,所有这些都在1个月内显示了完整的解决方案。没有患者经历过严重的并发症,如急性气道窘迫或出血。十四名患者能够从第一个术后早上口服,其余患者能够从术后第二天开始口服摄入。此外,没有患者术后患病。总之,在本研究中只与TPII相关联观察到尿道并发症。术后没有观察到吞咽困难,这是对其他治疗的优势。我们的研究结果表明TPII是ADSD的安全外科治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号